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A positive EarlyCDT, followed by CT scans significantly reduced the numbers of late stage
cancers: performance of the blood test should be assessed further in a screening study
where all eligible participants in the intervention arm have a CT scan.
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ABSTRACT
The EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that
could contribute to predicting lung cancer risk. Here we report on the results of a phase IV
biomarker evaluation of whether using the EarlyCDT-Lung test and any subsequent CT
scanning to identify those at high risk of lung cancer reduces the incidence of patients with
stage III/IV/Unspecified lung cancer at diagnosis, compared with the standard clinical
practice at the time the study began.
ECLS was a randomised controlled trial of 12,208 participants at risk of developing lung
cancer in Scotland. The intervention arm received the EarlyCDT-Lung test and, if test
positive, low-dose CT scanning six-monthly for up to two years. EarlyCDT-Lung test
negative and control arm participants received standard clinical care. Outcomes were
assessed at two years post-randomisation using validated data on cancer occurrence,
cancer staging, mortality and comorbidities.
At two years, 127 lung cancers were detected in the study population (1.0%).
In the intervention arm, 33/56 (58.9%) lung cancers were diagnosed at stage III/IV
compared to 52/71 (73.2%) in the control arm. The hazard ratio for stage III/IV
presentation was 0.64 (95% confidence interval 0.41, 0.99). There were non-significant
differences in lung cancer and all-cause mortality after two years.
ECLS compared EarlyCDT-Lung plus CT screening to standard clinical care (symptomatic
presentation), and was not designed to assess the incremental contribution of the
EarlyCDT-Lung test. The observation of a stage-shift towards earlier-stage lung cancer
diagnosis merits further investigations to evaluate whether the EarlyCDT-Lung test adds
anything to the emerging standard of LDCT.
Registration: ClinicalTrials.Gov registration number NCT01925625.
Funding Source: Scottish Government Health and Social Care Directorate, and
Oncimmune Ltd.
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INTRODUCTION
Five-year lung cancer mortality rates of 80-90% remain unacceptably high, and the UK’s
survival rate is poor by international comparisons.[1] To improve the poor prognosis,
methods that detect lung cancer at an earlier stage, when it is more likely to be treated
with curative intent, are needed. Several clinical trials have reported that low-dose
computed tomography (LDCT) screening can reduce lung cancer mortality by around
20%.[2–5] Most recently, the NELSON trial reported a 24% reduction in lung cancer
mortality from screening after 10-years of follow-up of 13,131 men.[4] However, no
difference in all-cause mortality was demonstrated in NELSON, nor in other large trials to
date with follow-up >5 years, including NLST.[3–9] That LDCT screening can reduce lung
cancer mortality has provided impetus to consider National screening programmes for the
early detection of lung cancer. However, the widespread adoption of LDCT screening will
likely remain limited by resource constraints and concerns about overdiagnosis.[10] Cost-
effective national screening programmes in the UK are likely to have to take a more
targeted approach to LDCT. A biomarker test could potentially play a role in identifying
those most at risk and who have most to gain from a targeted approach.[11]
The EarlyCDT-Lung test is an enzyme-linked immunosorbent assay (ELISA) that
measures seven autoantibodies (AABs), each with individual specificity for the following
tumour-associated antigens (TAA): p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and
SOX2. AABs can be detected in peripheral blood in patients with solid tumours up to 3-4
years before symptomatic presentation, although it is not yet clear how long AABs
continue to be present once triggered.[12, 13] In clinical studies of symptomatic lung
cancer and a high risk cohort study, the EarlyCDT-Lung test has demonstrated a
specificity of 91% and sensitivity ranging between 37-41% respectively.[14, 15] The ECLS
trial was a phase IV (prospective screening) biomarker evaluation that addressed the
question: ‘Does using the EarlyCDT-Lung Test to identify those at high risk of lung cancer
and any subsequent CT scanning reduce the incidence of patients with late-stage lung
cancer (III & IV) or unclassified presentation (U) at diagnosis, compared with standard
clinical practice?’.
The EarlyCDT-Lung test, an enzyme-linked immunosorbent assay (ELISA) that measures
seven autoantibodies (AABs), each with individual specificity for the following tumour-
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associated antigens (TAA): p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2.
AABs can be detected in peripheral blood in patients with solid tumours up to 3-4 years
before symptomatic presentation, although it is not yet clear how long AABs continue to be
present once triggered.[12, 13] In cohort studies, the EarlyCDT-Lung test has
demonstrated a specificity of 91% and sensitivity ranging between 37-41%.[14, 15] The
ECLS trial was a phase 4 (prospective screening) biomarker evaluation that addressed the
question: ‘Does using the EarlyCDT-Lung Test to identify those at high risk of lung cancer
and any subsequent CT scanning reduce the incidence of patients with late-stage lung
cancer (III & IV) or unclassified presentation (U) at diagnosis, compared with standard
clinical practice?’.
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METHODS
ECLS was a pragmatic randomised controlled trial involving 12,208 participants recruited
through General Practices and community-based recruitment strategies in Scotland.[16]
Recruitment occurred between April 2013 and July 2016, and follow-up was undertaken
for 24 months after randomisation for each participant. Adults age 50–75 at increased risk
of developing lung cancer compared to the general population were eligible to participate.
These were defined as current or former cigarette or tobacco smokers with at least 20
pack-years, or with a history of smoking of less than 20 pack-years plus immediate family
history (mother, father, sibling, child) of lung cancer. Potential trial participants were
identified from the electronic medical records of General Practices that were located in the
most socioeconomically deprived areas in Scotland, or they self-referred in response to a
range of advertising methods. Trial participants had no symptoms suggestive of current
malignancy, terminal illness or immunosuppressant therapy, and had an Eastern
Cooperative Oncology Group (ECOG) performance status of 0-2 at recruitment.
The study was conducted in accordance with the principles of Good Clinical Practice and
the UK National Research Governance Framework.[17] The University of Dundee and
Tayside Health Board co-sponsored the trial, which was registered with ClinicalTrials.Gov
(ID NCT01925625). Institutional Review Board approval was provided by the East of
Scotland Research Ethics Committee (REC Number 13/ES/0024). Funding for the trial
was obtained from the Scottish Government and the test manufacturer Oncimmune Ltd.
The trial was conducted in accordance with the protocol [16]; the protocol and the
statistical analysis plan are available in Appendix 1 & 2. An independent Trial Steering
Committee provided trial oversight. The report herein adheres to the CONSORT
Statement and Aarhus guidelines for the reporting of clinical trials on early cancer
diagnosis.[18, 19]
Randomisation and masking
All participants who gave informed consent provided a blood sample prior to
randomisation. Participants were then individually randomised, stratified by recruitment
site (Tayside, Glasgow, Lanarkshire) and minimized by age, sex and smoking status.
Smoking cessation advice was offered in keeping with NHS Scotland advice. Participants
allocated to the intervention arm were tested with the EarlyCDT-Lung test. If this was
Main paper: Sullivan et al., Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.
6
positive, they received a baseline chest X-ray (in order to prioritise access to CT for
patients with positive findings on CXR) and chest LDCT-scan followed by 6-monthly LDCT
scans up to 24 months post randomisation (Supplementary Table 1). Images from test-
positive participants were reviewed by a panel of experienced thoracic radiologists and
respiratory physicians. Test positive participants were followed-up within the study or via
the NHS care pathway (following the prevailing Fleischner society guidelines): whichever
was most intensive.[20] Participants allocated to the control arm, and those who were test
negative, received standard clinical care in the NHS in Scotland following National
guidelines for identification and management of symptoms suggestive of lung cancer with
no further study investigations.[21]
Blood samples were processed according to the Protocol (Appendix 1) and Standard
Operating Procedures, consistent with relevant UK and US guidelines. The EarlyCDT-
Lung test was performed on 0.5ml plasma samples. All test positive, and a random sample
of test negative and control arm participants recruited between December 2013 and April
2015, were invited to complete study questionnaires measuring psychological and
smoking outcomes, EQ5D, and health service use (Supplementary Table 2). Invitation to
complete the study questionnaires was done at one, three, six and 12 months for the test
negative and control arms, with additional questionnaire testing at 18 and 24 months for
participants in the test positive group. These results are reported elsewhere.[22, 23]
With participant consent, validated data on cancer occurrence, mortality and comorbidities
were obtained from National Services Scotland, which is a high-quality health services
data repository. These were linked and analysed in the Dundee Health Informatics Centre
Safe Haven.
Pathology and tumour staging reports were prepared by independent assessors who were
blinded to the allocation status of participants. Staging data were taken from the Scottish
Cancer Registry (SMR06).[24] The primary outcome variable extracted from SMR06 was
the first occurrence of all diagnoses starting with the International Statistical Classification
of Diseases and Related Health Problems 10th Revision codes (ICD-10) C33 (primary
malignant neoplasm of trachea) and C34 (bronchus or lung). Where more than one lung
cancer tumour was present at diagnosis, the most advanced tumour was used for
classification of disease. To determine staging, reported clinical and pathological “T, N, M”
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were used with pathological staging taking precedence when present by data analysts
blinded to allocation status. Lung tumour histology was coded in accordance with the Third
Edition International Classification of Diseases for Oncology and lung cancer staging was
determined using TNM 7th Edition.[25]
Sample size
During study planning, the background rate of lung cancer was 187/100,000 per year for
people aged 50-75 in Scotland. Those in the most deprived quintile were associated with
an increased risk of 1.8 times compared to the middle quintile of deprivation.[26, 27] The
ECLS study population was selected using similar entry criteria as the Mayo screening
study.[26] The precise baseline rate of stage III/IV presentation for the high-risk population
envisaged in this study was uncertain, as was the size of the reduction in stage III/IV
presentation likely to be achieved through use of EarlyCDT-Lung test. Based on the
literature and expert opinion, we estimated a stage III/IV presentation rate of 1200/100,000
per year in the control group, resulting in an estimated 2.4% prevalence rate over the two-
year follow-up period. Using this estimate, and 85% power at 5% significance (two-sided),
we wanted to be able to detect a 35% reduction in the rate of stage III/IV presentation in
the intervention arm. Based on discussion with a range of stakeholders, this was
considered likely to be sufficiently clinically significant to influence practice. Taken
together, we estimated the event rate over the two years of follow-up at 120 events in the
control arm and 78 events in the intervention arm, and required a sample size of n=5,000
per arm.
The protocol allowed for the sample size to be modified if the observed event rate proved
to be markedly different from the modelled estimates. The sample size was revised to
12,000 in 2015, after recruitment of approximately 8600 participants, when it appeared
that, while still meeting trial eligibility criteria, our initial assumption of the rate of stage
III/IV presentation had been overestimated. The increase in sample size was achieved by
adding an extra recruitment centre (Lanarkshire) and extending the recruitment period.
The revised power was 85% at 5% significance (two-sided) to detect a 35% reduction in
stage III/IV lung cancer, based on a rate of 600/100,000 with a 3-year recruitment period,
and two years follow-up, with no loss to follow-up anticipated.
Statistical Analysis
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The primary analysis compared the rate of stage III/IV lung cancer within two years of
randomisation between the intervention and control arms. The analyses followed the
intention to treat principle. Cox proportional hazards models were used to estimate the
hazard ratio. One participant who withdrew consent for use of their data was excluded
from analysis. The models were adjusted for age, gender, smoking history, socioeconomic
status and General Practice.
Similar methodology was used to analyse the secondary outcomes of mortality rates.
Further analysis compared the outcomes of those in the intervention arm with a positive
test, those with a negative test, and those in the control arm. Comparisons of proportions
were carried out using Fisher’s exact test due to the small number of events. Poisson
regression models, (adjusting for follow-up time when necessary) were used to investigate
other clinical outcomes. Specificity and sensitivity were calculated but these are estimated
values as the true figures are not estimable for early-stage and late-stage separately. This
is because the test positives received a more intensive intervention than the negatives,
and in a prospective study cancer status is unknown most of the time. The full statistical
analysis plan can be found in Appendix 2.
A within trial model-based cost-effectiveness analysis (CEA) was conducted estimating the
cost per stage I/II lung cancer case detected comparing the intervention to the control arm.
Diagnostic costs were included for all groups. A model-based approach was taken for two
reasons: (1) prevalence of lung cancer during the trial was different between arms; our
model assumed the same prevalence in both arms, and (2) data about resource use for
detection was only available for test positive participants (n=598) during the trial, therefore
resource use was modelled. Full assumptions and parameters used in the model are
presented in Appendix 3. Briefly, detection resources comprised the EarlyCDT-Lung test,
monitoring tests and confirmatory diagnostic tests. The outcome was number of stage I/II
lung cancers detected within the two-year follow-up. Treatment costs are not included in
this within-trial CEA.
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RESULTS
Characteristics of the participants
A total of 77,077 invitation letters were sent to people fulfilling the medical record search
criteria from 166 General Practices, and 16,268 responded. An additional 2389 potential
participants self-referred in response to advertising. 12,241 were invited to an in-person
screening appointment, and 12,215 were randomised. The recruitment rate of people
identified as potential study participants from General Practice records was 13.4%
(10,352/77,077). Six participants were excluded post-randomisation but prior to receiving
imaging because of ineligibility. One participant who withdrew consent for use of their data
was excluded from analysis leaving 12,208 participants. Participant characteristics were
balanced between arms (Table 1). 51.8% of participants lived in the two most deprived
quintiles, the mean age at recruitment was 60.5 years (S.D. 6.58), and the mean pack
years smoked was 38.2 (S.D. 18.58). The incidence rate of lung cancer in the trial
population, as determined from cancer registry data, was 520 per 100,000 per annum
(0.52%).
Adherence to protocol
We accessed the records of 99.9% of the study population and the CONSORT flowchart
(Figure 1) presents the end-point ascertainment in the intervention and control arms. The
CONSORT statement is available in Appendix 4.
Follow-up was performed using a national, closed administrative data system for 24
months after individual randomisation or to death if within the follow-up period. We also
checked national prescribing, and inpatient and outpatient data systems for activity relating
to trial participants in the two-year post-randomisation follow-up period. We confirmed
health service contacts in the two-year follow-up for 10,973 (89.9%) of the participants;
5489 in the intervention arm, and 5484 in the control arm. When the 1235 patients who did
not record health service contacts during this period were removed from the analysis, the
key findings were unchanged (Supplementary Data Pack 2).
Results of testing
The results of the primary analysis are presented in Table 2 and Figure 2. 9.8%
(598/6087) of participants in the intervention arm had a positive EarlyCDT-Lung test and
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3.0% (n=18) of these had a confirmed case of lung cancer within two years. In the test
negative arm, 0.7% (n=38) had confirmed lung cancers. For the intervention group as a
whole, 0.92% (n=56) had confirmed lung cancer within two years. In the control arm,
1.16% (n=71) had confirmed lung cancer within two years. The percentage of stage
III/IV/unspecified lung cancer diagnosis in the intervention and control arm was 0.5%
(33/6087) and 0.8% (52/6121), respectively. The absolute risk reduction in stage
III/IV/unspecified lung cancer diagnosis was 0.3% (95% CI = 0.01 to 0.6). The number of
participants to be screened to prevent one stage III/IV/unspecified lung cancer diagnosis
was 325 (95% CI 13 to 637) and the hazard ratio for stage III/IV presentation was 0.64
(95% CI 0.41 to 0.99; P=0.0432) (Supplementary Data Pack 2).
Although we did not perform an LDCT on all study subjects, the estimated test
performance characteristics, using cancer registry data after two years follow up as the
reference standard are described in Table 3. The EarlyCDT-Lung test had an estimated
sensitivity of 52.2% (95% CI = 30.6 to 73.2) for stage I/II disease and 18.2% (95% CI = 7.0
to35.5) for stage III/IV disease, and specificity of 90.3% (stage I/II; 95% CI = 89.6 to 91.1)
and 90.2% (stage III/IV; 95% CI = 89.4 to 91.0). The positive predictive value was 2.0% for
stage I/II disease (95% CI = 1.0 to 3.5) and 1.0% for stage III/IV disease (95% CI = 0.4 to
2.2), and the negative predictive value was 99.8% (stage I/II; 95% CI = 99.6 to 99.9) and
99.5% (stage III/IV; 95% CI = 99.3 to 99.7) in the population studied.
Figure 3 shows the secondary outcomes of lung cancer and all-cause mortality at two
years and demonstrates divergence after the first year of follow-up. In the intervention arm,
there were fewer events than the control arm for all-cause mortality. There were non-
significant differences in lung cancer mortality (intervention arm: 17/6082 (0.28%) vs.
control arm: 24/6121 (0.39%)) and all-cause mortality (intervention arm: 87/6082 (1.43%)
vs. control arm: 108/6121 (1.76%)) after two years. Participants in the intervention arm
were diagnosed with lung cancer on average 87.3 days earlier (mean: 303.0 days, 95% CI
214.9 to 364.0) compared to the control arm (mean: 390.3 days, 95% CI 340.6 to 440.1)
(Supplementary Data Pack 3).
The cost per early case (stage I/II) detected after two years was £116,000, with the 95%
CI ranging from £54,900 to dominated (i.e. screening using the EarlyCDT-Lung test would
be more costly and less effective than the control arm) (Supplementary Table 3).
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Sensitivity analyses were conducted varying prevalence and test costs; results indicate
that cost effectiveness was most affected by changes in prevalence. More detailed
analyses are planned to extrapolate the cost per case detected to a full lifetime cost per
quality-adjusted life year (QALY) gained analysis, including stage specific treatment costs
(Appendix 5). As not all required data are available at the time of writing this manuscript,
comprehensive cost-effectiveness analyses will be presented in a subsequent article.
Adverse events
Five adverse events, as defined in the protocol as being directly related to the intervention
(collection of blood sample), were reported and all were considered minor. For those in the
intervention arm, there was one injection site haematoma, one panic attack, and one pre-
syncope. In the control arm there were two episodes of syncope.
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CONCLUSIONS
This is the first trial conducted as a phase IV evaluation of a blood-based biomarker panel
for lung cancer. The results show a significant decrease in the incidence of advanced
stage disease, thereby meeting the primary endpoint of the study. In the study population
as a whole, the absolute risk reduction in stage III/IV lung cancer diagnosis for those in the
intervention arm was 0.3%. For those participants given a lung cancer diagnosis in the
study period, there was a 14.3% absolute risk reduction (33/56 vs 52/71) in stage III/IV
lung cancer presentation in the intervention arm. After the short follow-up period of two
years, there were non-significant reductions in lung cancer mortality - 29.2% relative risk
(control: 24, intervention: 17), and 19.4% in all-cause mortality (control: 108, intervention:
87).
Community-based trials like ECLS are more likely to produce generalizable results than
those conducted in academic health centres, which often recruit from a more tightly
selected population.[28] Strengths of our trial include community recruitment with a high
proportion of participants recruited by their General Practitioners from the two most
socioeconomically deprived quintiles (51.8%) of the Scottish population; integration with a
national health care system providing whole population care; a high end-point
ascertainment rate (>99.9%); and the intention to treat analysis.
The lung cancer diagnosis rate (1%) was lower than we anticipated when planning the
study and lower than might be expected from other studies using LDCT. This approach
therefore, in contrast to LDCT, may have missed early stage lung cancers. Our follow up
period of two years was short and cases will continue to emerge as the study final results
become available. Another potential contributor to the lower rate of diagnosis may be the
“healthy volunteer” effect, which may have led to a higher rate of recruitment of the
healthiest among the at-risk population meeting our inclusion criteria.[31] It is worth noting
that even with a lower rate of lung cancer, those in the intervention arm were at a
statistically significant and clinically important reduced risk of stage III/IV presentation. The
results of this study are not directly comparable to those using a validated questionnaire
before LDCT.[32] A direct comparison of both methods would need to be undertaken to
determine how a biomarker test compares to a questionnaire followed by LDCT. A control
arm involving CT screening would have provided evidence comparing the United States
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Preventive Task Force (USPTF) guidelines against a ‘biomarker first’ approach, but CT
screening was not available when the ECLS trial started, and remains unavailable in many
health systems, including the UK.
The finding that there were more lung cancers in the control arm (71 compared to 56 in the
intervention arm) was also unexpected as CT screening trials usually report more cancers
diagnosed in the intervention arm. We consider that there are five potential reasons for
this. Firstly, as discussed above, we may have not diagnosed all cases of lung cancer.
Secondly, although treatment arms were well balanced due to randomisation there may be
differences between arms in unmeasured risk factors, such as asbestos exposure.[29]
False reassurance in the test negative arm (leading to risk-reduction behaviours in those
receiving the EarlyCDT test) may also be a potential explanation. A recent systematic
review found that negative test results are unlikely to cause false reassurance, anxiety or a
change in health-related behaviours, hence we consider it unlikely that false reassurance
had a substantial impact on lung cancer presentation in those with negative test
results.[30] Finally, the observed numerical difference is not statistically significant and
could be due to chance (p=0.2)
We have presented a short-term within-trial analysis of cost effectiveness data. A recent
study has suggested that the use of an autoantibody test in patients with pulmonary
nodules is a cost-effective use of healthcare resources.[33] The base case cost per QALY
of £116K is a within-trial estimate and does not include long-term costs of treatment and
survival beyond the trial. Longer-term analyses will employ a model to link the short-term
outcomes measured within the trial to longer-term health impacts (e.g. morbidity,
mortality), and will consider the longer-term impact of early detection and treatment on the
cost-per QALY gained in the context of more effective and expensive therapies.
The seven autoantibodies to the TAA panel of the EarlyCDT-Lung test demonstrated high
specificity (90.3%), and moderate sensitivity at 32.1% for detecting lung cancer at two
years. The moderate sensitivity of the test at two years may be due to tumour-induced
suppression of immune responses that lead to less autoantibody production and
detection.[34] The study measured the EarlyCDT-Lung test only once at baseline and so
does not address the frequency at which the test might be repeated. A previous report
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showed that in patients with lung nodules the EarlyCDT-Lung test enhanced the positive
predictive power of nodule-based risk assessment for the detection of lung cancer.[35] The
high specificity of the EarlyCDT-Lung test could be used in combination with LDCT, which
demonstrates high sensitivity, to ensure a high detection rate of stage I/II lung cancer
cases. Recent developments in the use of Artificial Intelligence in imaging and other
biomarkers are also likely to be important.[36]
In conclusion, ECLS demonstrates that blood-based biomarker panels, such as the
EarlyCDT-Lung test, followed by LDCT, can detect stage I/II lung cancer. Follow-up
analyses will be performed after 5 and 10 years, although we recognise that the absolute
lung cancer incidence would be higher than that detected due to deaths from other
causes. Further investigation in large, community-based studies will be required to
determine the long-term impact of performing the EarlyCDT-Lung test with LDCT on
mortality, cost-effectiveness, the level of risk that should be targeted, the time interval
between tests, and how to improve the engagement of people at the highest risk.[37]
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Tables and Figures.
Table 1. Selected Baseline Characteristics of the Trial Participants.
Intervention Control




50-54 yrs 1393 (22.9) 1409 (23.0)
55-59 yrs 1562 (25.7) 1531 (25.0)
60-64 yrs 1300 (21.4) 1318 (21.5)
65-69 yrs 1179 (19.4) 1203 (19.7)
70-75 yrs 654 (10.7) 660 (10.8)
Sex
Male 3095 (50.8) 3129 (51.1)
Female 2993 (49.2) 2992 (48.9)
SIMD quintiles (1= most deprived)
Quintile 1 1751 (28.8) 1726 (28.2)
Quintile 2 1431 (23.5) 1420 (23.2)
Quintile 3 1108 (18.2) 1121 (18.3)
Quintile 4 966 (15.9) 1002 (16.4)
Quintile 5 782 (12.8) 792 (12.9)
No information 50 (0.8) 60 (1.0)
Smoking status
Current 3199 (52.5) 3178 (51.9)
Former 2889 (47.5) 2943 (48.1)
Quit  ≥ 1 week 2207 (36.3) 2283 (37.3) 
Quit ≥ 6 months 1998 (32.8) 2083 (34.0) 
Mean pack years ± SD 38.4 ± 18.7 38.0 ± 18.5
Family history 1550 (25.5) 1614 (26.4)
Comorbidity
COPD 306 (5.0) 287 (4.7)
Legend: SIMD- Scottish Index of Multiple Deprivation; SD- standard deviation; COPD-
Chronic Obstructive Pulmonary Disease.
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Figure 1. CONSORT flowchart.













§ Primary care (n=10352)
§ Self-referral (n=1889)
Not proceeding (n=26)
Allocated to intervention (n=6088)
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Requesting contact (n=18657) Not proceeding (n=6416)
§ No further contact (n=2202)
§ Not eligible (n=2963)
§ Declined (n=1251)
Primary care invitations (n=77077)
Self-referral (n=2389)
Excluded (n=6)
§ Ineligible error (n=1)
§ Randomisation error (n=1)
§ Duplicate records (n=4)
No response (n=60809)








Allocated to control (n=6121)
Test negative (n=5489)
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Table 2. Stage of Lung Cancer at Diagnosis in the Intervention and Control Arms.
Intervention Control
Test positive Test negative Standard Clinical Care
(N=598) (N=5489) (N=6121)
Stage number (percent) number (percent)
I 10 (1.7) 7 (0.1) 9 (0.1)
II 2 (0.3) 4 (0.1) 10 (0.2)
III 3 (0.5) 12 (0.2) 17 (0.3)
IV 3 (0.5) 15 (0.3) 28 (0.5)
Unspecified 0 (0.0) 0 (0.0) 7 (0.1)
No Lung Cancer 580 (97.0) 5451 (99.3) 6050 (98.8)
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Figure 2. Primary Outcome: Diagnosis of Stage III/IV/Unspecified Lung Cancer Two
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% value (95% CI)
Specificity
% value (95% CI)
PPV
% value (95% CI)
NPV
% value (95% CI)
Six Months After Randomisation (post-hoc)
I & II 7 (1.2) 2 (0.0) 77.8 (40.0, 97.2) 90.3 (89.5, 91.0) 1.2 (0.5, 2.4) 100.0 (99.9, 100.0)
III & IV 5 (0.8) 8 (0.2) 38.5 (13.9, 68.4) 90.2 (89.5, 91.0) 0.8 (0.3, 1.9) 99.9 (99.7, 99.9)
I - IV 12 (2.0) 10 (0.2) 54.6 (32.2, 75.6) 90.3 (89.6, 91.1) 2.0 (1.0, 3.5) 99.8 (99.7, 99.9)
One Year After Randomisation (post-hoc)
I & II 9 (1.5) 4 (0.1) 69.2 (38.6, 90.9) 90.3 (89.5, 91.0) 1.5 (0.7, 2.8) 99.9 (99.8, 100.0)
III & IV 6 (1.0) 14 (0.2) 30.0 (11.9, 54.3) 90.2 (89.5, 91.0) 1.0 (0.4, 2.2) 99.7 (99.6, 99.9)
I - IV 15 (2.5) 18 (0.3) 45.5 (28.1, 63.6) 90.4 (89.6, 91.1) 2.5 (1.4, 4.1) 99.7 (99.5, 99.8)
Two Years After Randomisation
I & II 12 (2.0) 11 (0.2) 52.2 (30.6, 73.2) 90.3 (89.6, 91.1) 2.0 (1.0, 3.5) 99.8 (99.6, 99.9)
III & IV 6 (1.0) 27 (0.5) 18.2 (7.0, 35.5) 90.2 (89.4, 91.0) 1.0 (0.4, 2.2) 99.5 (99.3, 99.7)
I - IV 18 (3.0) 38 (0.7) 32.1 (20.3, 46.0) 90.4 (89.6, 91.1) 3.0 (1.8, 4.7) 99.3 (99.1, 99.5)
Legend: PPV- positive predictive value; NPV- negative predictive value; CI- confidence interval.
Note: Absolute risk reduction of late-stage lung cancer diagnosis 2 years after randomisation was 0.31%. The number needed to screen to
prevent one late-stage lung cancer diagnosis 2 years after randomisation was 325 (95% CI: 13, 637).
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Figure 3. Secondary Outcomes: Mortality Two Years After Randomisation in the
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